Immune checkpoint inhibition in COVID-19: risks and benefits

References

• Wang K, Qiu Z, Liu J, et al. Analysis of the clinical characteristics of 77 COVID-19 deaths. Sci Rep. 2020;10(1):16384.
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhou X, Qiu Y, et al. Clinical characteristics of 82 cases of death from COVID-19. Plos One. 2020;15(7):e0235458–e0235458.
   PubMed Web of Science ®Google Scholar
• Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov. 2020;10(7):935–941.
   PubMed Web of Science ®Google Scholar
• Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying Immunoreceptor. Immunity. 1999;11(2):141–151.
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8(3): p. 239–245.
   Google Scholar
• Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–242.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26(1):677–704.
   PubMed Web of Science ®Google Scholar
• Wykes MN, Lewin SR. Immune checkpoint blockade in infectious diseases. Nat Rev Immunol. 2018;18(2): p. 91–104.
   Google Scholar
• Cai H, Liu G, Zhong J, et al. Immune checkpoints in viral infections. Viruses. 2020;12(9):1051. .
   Web of Science ®Google Scholar
• D’Souza M, Fontenot AP, Mack DG, et al. Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction. J Immunol. 2007 Aug 1;179(3):1979–1987.
   PubMed Web of Science ®Google Scholar
• Cecchinato V, Tryniszewska E, Ma ZM, et al. Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J Immunol. 2008;180(8):5439–5447.
   PubMed Web of Science ®Google Scholar
• Cook MR, Kim C. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review. JAMA Oncol. 2019 Jul 1;5(7):1049–1054.
   PubMed Web of Science ®Google Scholar
• Uldrick TS, Ison G, Rudek MA, et al. Modernizing clinical trial eligibility criteria: recommendations of the American society of clinical oncology-friends of cancer research HIV working group. J Clin Oncol. 2017 Nov 20;35(33):3774–3780.
   PubMed Web of Science ®Google Scholar
• Pu D, Yin L, Zhou Y, et al. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: a systematic review. Medicine (Baltimore). 2020 Jan;99(5):e19013. .
   PubMed Web of Science ®Google Scholar
• Pertejo-Fernandez A, Ricciuti B, Hammond SP, et al. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. Lung Cancer. 2020 Jul;145:181–185.
   PubMed Web of Science ®Google Scholar
• Tapia Rico G, Chan MM, Loo KF. The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): a review of the available evidence. Cancer Treat Rev. 2020 Jun;86:102011.
   PubMed Web of Science ®Google Scholar
• Dai M-Y, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multi-center study during the COVID-19 outbreak. Cancer Discov. 2020
   Google Scholar
• Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3): p. 335–337.
   Google Scholar
• Hou H, Zhang B, Huang H, et al. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19. Clin Exp Immunol. 2020;201(1):76–84.
   PubMed Web of Science ®Google Scholar
• Liu Z, Long W, Tu M, et al. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19. J Infect. 2020;81(2):318–356.
   Web of Science ®Google Scholar
• Thibaudin M, Fumet J-D, Bon M, et al. Immunological features of coronavirus disease 2019 in patients with cancer. Eur J Cancer. 1990;2020(139):70–80.
   Google Scholar
• Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827.
   PubMed Web of Science ®Google Scholar
• Saheb Sharif-Askari N, Saheb Sharif-Askari F, Mdkhana B, et al. Enhanced expression of immune checkpoint receptors during SARS-CoV-2 viral infection. Mol Ther Methods Clin Dev. 2021 Mar 12;20:109–121.
   PubMed Web of Science ®Google Scholar
• Kong Y, Wang Y, Wu X, et al. Storm of soluble immune checkpoints associated with disease severity of COVID-19. Signal Transduct Target Ther. 2020;5(1):192.
   Google Scholar
• Jiang Y, Wei X, Guan J, et al. COVID-19 pneumonia: CD8(+) T and NK cells are decreased in number but compensatory increased in cytotoxic potential. Clin Immunol. 2020;218:108516.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422.
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229): p. 1033–1034.
   Google Scholar
• Mojtabavi H, Saghazadeh A, Rezaei N. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis. Eur Cytokine Netw. 2020;31(2):44–49.
   PubMed Web of Science ®Google Scholar
• Rokni M, Hamblin MR, Rezaei N. Cytokines and COVID-19: friends or foes? Hum Vaccin Immunother. 2020;16(10):2363–2365.
   PubMed Web of Science ®Google Scholar
• Ceschi A, Noseda R, Palin K, et al. Immune checkpoint inhibitor-related cytokine release syndrome: analysis of WHO global pharmacovigilance database. Front Pharmacol. 2020;11:557.
   PubMed Web of Science ®Google Scholar
• Rotz SJ, Leino D, Szabo S, et al. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatr Blood Cancer. 2017;64(12):12. .
   Web of Science ®Google Scholar
• Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154–5157.
   PubMed Web of Science ®Google Scholar
• Mazzoni A, Salvati L, Maggi L, et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest. 2020;130(9):4694–4703.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther Adv Respir Dis. 2016;10(3):183–193.
   PubMed Web of Science ®Google Scholar
• Zhai X, Zhang J, Tian Y, et al. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients. Cancer Biol Med. 2020 Aug 15;17(3):599–611.
   PubMed Web of Science ®Google Scholar
• Cui P, Liu Z, Wang G, et al. Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: a case-control study. Cancer Med. 2018 Aug;7(8):4115–4120.
   PubMed Web of Science ®Google Scholar
• Rossi E, Schinzari G, Tortora G. Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment. J Immunother Cancer. 2020 Jul;8(2):2.
   Web of Science ®Google Scholar
• Chang HL, Wei PJ, Wu KL, et al. Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic. Lung Cancer. 2020 Aug;146:376–377.
   PubMed Web of Science ®Google Scholar
• Lee LYW, Cazier J-B, Starkey T, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21(10):1309–1316.
   PubMed Web of Science ®Google Scholar
• Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov. 2020;10(7):935.
   PubMed Web of Science ®Google Scholar
• Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):904–913.
   PubMed Web of Science ®Google Scholar
• Lee LYW, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919–1926.
   PubMed Web of Science ®Google Scholar
• Luo J, Rizvi H, Egger JV, et al. Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers. Cancer Discov. 2020;10(8): p. 1121–1128.
   Google Scholar
• Gonzalez-Cao M, Antonazas-Basa M, Puertolas T, et al. Cancer immunotherapy does not increase the risk of death by COVID-19 in melanoma patients. medRxiv. 2020 ;2020:05–19. 20106971.
   Google Scholar
• Robilotti EV, Babady NE, Mead PA, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26(8):1218–1223.
   PubMed Web of Science ®Google Scholar
• Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783. .
   PubMed Web of Science ®Google Scholar
• Specialty guides for patient management during the coronavirus pandemic.
   Google Scholar
• You B, Ravaud A, Canivet A, et al. The official French guidelines to protect patients with cancer against SARS-CoV-2 infection. Lancet Oncol. 2020;21(5):619–621.
   PubMed Web of Science ®Google Scholar
• Mansourabadi AH, Sadeghalvad M, Mohammadi-Motlagh H-R, et al. The immune system as a target for therapy of SARS-CoV-2: a systematic review of the current immunotherapies for COVID-19. Life Sci. 2020;258:118185.
   PubMed Web of Science ®Google Scholar
• Pashaei M, Rezaei N. Immunotherapy for SARS-CoV-2: potential opportunities. Expert Opin Biol Ther. 2020;20(10):1111–1116.
   PubMed Web of Science ®Google Scholar
• André P, Denis C, Soulas C, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NKCells. Cell. 2018;175(7):1731–1743.e13.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang H, He Y-W. The complement receptors C3aR and C5aR are a new class of immune checkpoint receptor in cancer immunotherapy. Front Immunol. 2019;10:1574.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Huang Z, Yin G, et al. Study of the lymphocyte change between COVID-19 and non-COVID-19 pneumonia cases suggesting other factors besides uncontrolled inflammation contributed to multi-organ injury. SSRN Electron J. 2020;2020:02–19. 20024885.
   Google Scholar
• Hotchkiss RS, Colston E, Yende S, et al. Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. Intensive Care Med. 2019;45(10):1360–1371.
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Colston E, Yende S, et al. Immune checkpoint inhibition in sepsis. Crit Care Med. 2019;47(5):632–642.
   PubMed Web of Science ®Google Scholar
• McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol. 2019 Apr 26;37(1):457–495.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013 Oct 1;19(19):5300–5309.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571.
   PubMed Web of Science ®Google Scholar
• Zeng T, Qin Q, Bian Z, et al. Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC). Artif Cells Nanomed Biotechnol. 2019;47(1):4194–4201.
   PubMed Web of Science ®Google Scholar
• Stühler V, Maas JM, Rausch S, et al. Immune checkpoint inhibition for the treatment of renal cell carcinoma. Expert Opin Biol Ther. 2020;20(1):83–94.
   PubMed Web of Science ®Google Scholar
• Ghanizada M, Jakobsen KK, Grønhøj C, et al. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: a systematic review. Oral Oncol. 2019;90:67–73.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory hodgkin’s lymphoma. N Engl J Med. 2014;372(4):311–319.
   PubMed Web of Science ®Google Scholar
• Vaddepally RK, Kharel P, Pandey R, et al. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence.Cancers (Basel). 2020
   Google Scholar
• ElKassar N, Gress RE. An overview of IL-7 biology and its use in immunotherapy. J Immunotoxicol. 2010;7(1):1–7.
   PubMed Web of Science ®Google Scholar